BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced that the European Medicines Evaluation Agency (EMEA) designated sapacitabine as an orphan medicine in two separate indications: Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).
